BRAF and neoplasm: Kaye et al. first reported an African American ameloblastoma patient with recurrent metastases bearing somatic BRAF p.V600E mutation (detected by mutant-specific antibody with immunohistochemistry), treated with compassionate dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) and exhibited immediate marked tumor reduction at day 4, followed by disappearance of lung metastases and shrinkage of head and neck lesions at week 8, and persistent antitumor responses even at 20 weeks69.